Samsung Biologics has agreed to acquire GlaxoSmithKline’s Human Genome Sciences and its two pharmaceutical manufacturing facilities in Rockville, Maryland for about 280 million US dollars.

This move marks Samsung Biologics’ first major production footprint in the United States and reflects a strategic push into US biomanufacturing amid rising demand for biologics. The site includes 60,000 liters of drug substance capacity and can handle both clinical and commercial production.

Samsung Biologics said it plans further investments to increase capacity and upgrade technologies to better support supply chains for critical biologic medicines for patients. The Korean contract development and manufacturing organisation intends to retain more than 500 employees at the site after the deal closes.

The acquisition continues a long history of collaboration between the two companies, as Samsung Biologics previously partnered with GSK under manufacturing agreements that saw the Korean CDMO help produce GSK’s biologic therapies. The transaction is expected to be finalised by the end of the first quarter of 2026.